Adverse effects of GLP – 1 Receptor Agonists
Introduction and purpose Glucagon-like peptide-1 receptor agonists (GLP – 1 RAs) are indicated in type 2 diabetes (T2D) and obesity because of their high efficacy in controlling blood glucose levels and inducing weight loss. Patients may develop gastrointestinal adverse effects (GI AEs) such as nau...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Kazimierz Wielki University
2025-02-01
|
| Series: | Journal of Education, Health and Sport |
| Subjects: | |
| Online Access: | https://apcz.umk.pl/JEHS/article/view/57774 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1823856481849573376 |
|---|---|
| author | Anna Kasprzak Monika Kułaga Monika Grzybek Diana Mazur-Lesińska Barbara Szostak Sylwia Wielgosz-Biała Krzysztof Tyszkiewicz Borys Łozowski Małgorzata Kasprzak Barbara Wilczyńska |
| author_facet | Anna Kasprzak Monika Kułaga Monika Grzybek Diana Mazur-Lesińska Barbara Szostak Sylwia Wielgosz-Biała Krzysztof Tyszkiewicz Borys Łozowski Małgorzata Kasprzak Barbara Wilczyńska |
| author_sort | Anna Kasprzak |
| collection | DOAJ |
| description |
Introduction and purpose
Glucagon-like peptide-1 receptor agonists (GLP – 1 RAs) are indicated in type 2 diabetes (T2D) and obesity because of their high efficacy in controlling blood glucose levels and inducing weight loss. Patients may develop gastrointestinal adverse effects (GI AEs) such as nausea, vomiting, diarrhoea, constipation and, less commonly, pancreatitis and cholelithiasis. In addition, a recent retrospective cohort study suggested a possible association between nonarteritic anterior ischaemic optic neuropathy (NAION) and the use of one of the GLP – 1 RAs, semaglutide. The aim of this article is to review the side effects associated with GLP – 1 RAs therapy.
|
| format | Article |
| id | doaj-art-2877ed247b474dc7bfc149246be4ff58 |
| institution | Kabale University |
| issn | 2391-8306 |
| language | English |
| publishDate | 2025-02-01 |
| publisher | Kazimierz Wielki University |
| record_format | Article |
| series | Journal of Education, Health and Sport |
| spelling | doaj-art-2877ed247b474dc7bfc149246be4ff582025-02-12T08:17:45ZengKazimierz Wielki UniversityJournal of Education, Health and Sport2391-83062025-02-017810.12775/JEHS.2025.78.57774Adverse effects of GLP – 1 Receptor AgonistsAnna Kasprzak0https://orcid.org/0009-0002-1491-245XMonika Kułaga1https://orcid.org/0009-0001-3949-2124Monika Grzybek2https://orcid.org/0009-0003-2246-800XDiana Mazur-Lesińska3https://orcid.org/0009-0000-2489-9100Barbara Szostak4https://orcid.org/0009-0000-8035-7584Sylwia Wielgosz-Biała5https://orcid.org/0009-0003-0567-5998Krzysztof Tyszkiewicz6https://orcid.org/0009-0005-0208-2286Borys Łozowski7https://orcid.org/0000-0002-1990-040XMałgorzata Kasprzak8https://orcid.org/0009-0007-3791-1632Barbara Wilczyńska9https://orcid.org/0009-0001-4939-7550Department of Internal Medicine, Endocrinology and Diabetology Cardinal Stefan Wyszyński Provincial Specialist Hospital in LublinDepartment of Internal Medicine, Endocrinology and Diabetology Stefan Cardinal Wyszyński Provincial Specialist Hospital SPZOZ in LublinDepartment od Internal Medicine, Endocrinology and Diabetology Stefan Cardinal Wyszyński Provincial Specialist Hospital in LublinDepartment od Internal Medicine, Endocrinology and Diabetology Stefan Cardinal Wyszyński Provincial Specialist Hospital in LublinDepartment od Internal Medicine, Endocrinology and Diabetology Stefan Cardinal Wyszyński Provincial Specialist Hospital in LublinDepartment od Internal Medicine, Endocrinology and Diabetology Stefan Cardinal Wyszyński Provincial Specialist Hospital in LublinDepartment od Internal Medicine, Endocrinology and Diabetology Stefan Cardinal Wyszyński Provincial Specialist Hospital in LublinDepartment of Gastroenterology, University Clinical Hospital No 4 in LublinDepartment od Internal Medicine, Stefan Cardinal Wyszyński Provincial Specialist Hospital in LublinDepartment of Pediatrics and Allergology, University Children's Hospital in Lublin Introduction and purpose Glucagon-like peptide-1 receptor agonists (GLP – 1 RAs) are indicated in type 2 diabetes (T2D) and obesity because of their high efficacy in controlling blood glucose levels and inducing weight loss. Patients may develop gastrointestinal adverse effects (GI AEs) such as nausea, vomiting, diarrhoea, constipation and, less commonly, pancreatitis and cholelithiasis. In addition, a recent retrospective cohort study suggested a possible association between nonarteritic anterior ischaemic optic neuropathy (NAION) and the use of one of the GLP – 1 RAs, semaglutide. The aim of this article is to review the side effects associated with GLP – 1 RAs therapy. https://apcz.umk.pl/JEHS/article/view/57774type 2 diabetesobesity, glucagon – like peptide – 1 receptor agonistshypoglycemiagastrointestinal adverse effectsnonarteritic anterior ischaemic optic neuropathy |
| spellingShingle | Anna Kasprzak Monika Kułaga Monika Grzybek Diana Mazur-Lesińska Barbara Szostak Sylwia Wielgosz-Biała Krzysztof Tyszkiewicz Borys Łozowski Małgorzata Kasprzak Barbara Wilczyńska Adverse effects of GLP – 1 Receptor Agonists Journal of Education, Health and Sport type 2 diabetes obesity, glucagon – like peptide – 1 receptor agonists hypoglycemia gastrointestinal adverse effects nonarteritic anterior ischaemic optic neuropathy |
| title | Adverse effects of GLP – 1 Receptor Agonists |
| title_full | Adverse effects of GLP – 1 Receptor Agonists |
| title_fullStr | Adverse effects of GLP – 1 Receptor Agonists |
| title_full_unstemmed | Adverse effects of GLP – 1 Receptor Agonists |
| title_short | Adverse effects of GLP – 1 Receptor Agonists |
| title_sort | adverse effects of glp 1 receptor agonists |
| topic | type 2 diabetes obesity, glucagon – like peptide – 1 receptor agonists hypoglycemia gastrointestinal adverse effects nonarteritic anterior ischaemic optic neuropathy |
| url | https://apcz.umk.pl/JEHS/article/view/57774 |
| work_keys_str_mv | AT annakasprzak adverseeffectsofglp1receptoragonists AT monikakułaga adverseeffectsofglp1receptoragonists AT monikagrzybek adverseeffectsofglp1receptoragonists AT dianamazurlesinska adverseeffectsofglp1receptoragonists AT barbaraszostak adverseeffectsofglp1receptoragonists AT sylwiawielgoszbiała adverseeffectsofglp1receptoragonists AT krzysztoftyszkiewicz adverseeffectsofglp1receptoragonists AT borysłozowski adverseeffectsofglp1receptoragonists AT małgorzatakasprzak adverseeffectsofglp1receptoragonists AT barbarawilczynska adverseeffectsofglp1receptoragonists |